Prospective Non-Interventional Study Evaluating the Long-term Safety of Odevixibat in Patients With Alagille Syndrome (ALGS)
Status: Recruiting
Location: See all (14) locations...
Study Type: Observational
SUMMARY
This study will collect information from patients with ALGS who are using odevixibat in their daily lives. Odevixibat is a medication that helps patients with ALGS, a rare disease that affects the liver and causes itching. The main aim of this study is to observe the long-term, everyday safety of the drug odevixibat in patients with ALGS who are receiving ongoing treatment.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 6 months
Healthy Volunteers: f
View:
• Diagnosed with ALGS.
• On (or starting) active odevixibat treatment.
• Aged 6 months or older at the time of consent.
Locations
Other Locations
France
Hospices Civils de Lyon - Hopital Femme Mere Enfant
NOT_YET_RECRUITING
Bron
CHU Dijon Bourgogne
NOT_YET_RECRUITING
Dijon
APHP - Hopital Bicetre - Paris Sud
NOT_YET_RECRUITING
Le Kremlin-bicêtre
APHM - CHU Timone
NOT_YET_RECRUITING
Marseille
CHU de Montpellier - Hopital Saint Eloi
NOT_YET_RECRUITING
Montpellier
APHP - Hopital Necker-Enfants Malades
NOT_YET_RECRUITING
Paris
CHU de Toulouse - Hopital Paule de Viguier
NOT_YET_RECRUITING
Toulouse
APHP - Centre Hepato-Biliaire Hospital Paul Brousse
NOT_YET_RECRUITING
Villejuif
Italy
Azienda Ospedaliero Universitaria Meyer
RECRUITING
Florence
Azienda Ospedaliera Di Rilievo Nazionale Santobono Pausilipon
NOT_YET_RECRUITING
Naples
University Hospital Of Padova
NOT_YET_RECRUITING
Padova
IRCCS Ospedale Pediatrico Bambino Gesu
NOT_YET_RECRUITING
Roma
A.O.U. Citta della Salute e della Scienza di Torino - Ospedale Infantile Regina Margherita
NOT_YET_RECRUITING
Torino
Ospedale Universitario Di Udine
NOT_YET_RECRUITING
Udine
Contact Information
Primary
Ipsen Clinical Study Enquiries
clinical.trials@ipsen.com
See e mail
Time Frame
Start Date: 2026-07-10
Estimated Completion Date: 2031-09-30
Participants
Target number of participants: 30
Related Therapeutic Areas
Sponsors
Leads: Ipsen